Skip to main content
. 2022 Jan 6;13:32–45. doi: 10.18632/oncotarget.28168

Figure 6. SHMT2 expression is increased in metastatic NB cells.

Figure 6

RT-qPCR and immunoblotting were used to assess SHMT2 mRNA and protein expression, respectively, in the highly aggressive pro-metastatic cell line, LM2, and the BE(2)-C parental cell line. (A) SHMT2 mRNA expression is markedly increased in the metastatic cell line LM2 compared to parental cells. (B) SHMT2 protein expression is increased in LM2 compared to parental cells. (C) Densitometry analysis, reported as a ratio of each protein band density relative to the density of each β-actin control band (protein density: β-actin density), demonstrates SHMT2 protein expression is 2.7 times higher in metastatic LM2 cells compared to the BE(2)-C parent cells. (D) R2 genomics database analysis of SHMT2 gene expression based on disease stage demonstrates increasing SHMT2 expression with increasing disease stage in neuroblastoma. The highest SHMT2 expression was seen in patients with stage 4, metastatic disease.